Document is current
Any future updates will be listed below
-
Authors
Sakuma, Mayu https://orcid.org/0009-0007-1118-0472
Suzuki, Shinya
Hirota, Naomi
Motogi, Jun
Umemoto, Takuya
Nakai, Hiroshi
Matsuzawa, Wataru
Takayanagi, Tsuneo
Hyodo, Akira
Satoh, Keiichi
Arita, Takuto
Yagi, Naoharu
Kishi, Mikio
Semba, Hiroaki
Kano, Hiroto
Matsuno, Shunsuke
Kato, Yuko
Otsuka, Takayuki
Yajima, Junji
Takeishi, Yasuchika
Uejima, Tokuhisa
Oikawa, Yuji
Yamashita, Takeshi
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP17ek0210082)
Grants-in-Aid for Scientific Research, Kakenhi (24K19071)
- License Information
-
More Information
Article History
Received: 3 October 2024
Accepted: 16 April 2025
First Online: 15 May 2025
Declarations
:
: Dr. Suzuki received research funding from Mitsubishi Tanabe Pharm and Daiichi Sankyo. Dr. Yamashita received research funds and/or lecture fees from Daiichi Sankyo, Bayer Yakuhin, Bristol-Myers Squibb, Pfizer, Nippon Boehringer Ingelheim, Eisai, Mitsubishi Tanabe Pharm, Ono Pharmaceutical, and Toa Eiyo.
: This study was performed in accordance with the ethical norms based on the Declaration of Helsinki (revised in 2013) and Ethical Guidelines for Medical and Health Research Involving Human Subjects (Public Notice of the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare, Japan, issued in 2017). Written informed consent was obtained from all participants. The study protocol was reviewed by the Institutional Review Board of the Cardiovascular Institute.
: Not applicable.
